C
6.81
-0.20 (-2.85%)
| Previous Close | 7.01 |
| Open | 6.96 |
| Volume | 203,238 |
| Avg. Volume (3M) | 352,675 |
| Market Cap | 336,622,368 |
| Price / Sales | 1.38 |
| Price / Book | 0.870 |
| 52 Weeks Range | |
| Earnings Date | 10 Mar 2025 - 14 Mar 2025 |
| Profit Margin | -50.25% |
| Operating Margin (TTM) | -27.44% |
| Diluted EPS (TTM) | -2.49 |
| Quarterly Revenue Growth (YOY) | 4.00% |
| Total Debt/Equity (MRQ) | 62.38% |
| Current Ratio (MRQ) | 5.29 |
| Operating Cash Flow (TTM) | -16.32 M |
| Levered Free Cash Flow (TTM) | -9.81 M |
| Return on Assets (TTM) | -4.98% |
| Return on Equity (TTM) | -25.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Integrated Freight & Logistics (US) | Bearish | Bearish |
| Integrated Freight & Logistics (Global) | Bearish | Bearish | |
| Stock | CryoPort, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.5
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -1.50 |
|
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas. |
|
| Sector | Industrials |
| Industry | Integrated Freight & Logistics |
| Investment Style | Small Value |
| % Held by Insiders | 2.67% |
| % Held by Institutions | 101.12% |
| 52 Weeks Range | ||
| Median | 11.00 (61.53%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 05 Mar 2025 | 11.00 (61.53%) | Buy | 6.61 |
| 17 Jan 2025 | 11.00 (61.53%) | Buy | 7.50 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SAWICKI MARK W | - | 4.70 | -1,583 | -7,440 |
| SHELTON JERRELL | - | 4.70 | -4,173 | -19,613 |
| STEFANOVICH ROBERT | - | 4.70 | -1,256 | -5,903 |
| Aggregate Net Quantity | -7,012 | |||
| Aggregate Net Value ($) | -32,956 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 4.70 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STEFANOVICH ROBERT | Officer | 10 Mar 2025 | Sell (-) | 1,256 | 4.70 | 5,903 |
| SHELTON JERRELL | Officer | 10 Mar 2025 | Sell (-) | 4,173 | 4.70 | 19,613 |
| SAWICKI MARK W | Officer | 10 Mar 2025 | Sell (-) | 1,583 | 4.70 | 7,440 |
| STEFANOVICH ROBERT | Officer | 09 Mar 2025 | Option execute | 2,667 | - | - |
| SHELTON JERRELL | Officer | 09 Mar 2025 | Option execute | 8,250 | - | - |
| SAWICKI MARK W | Officer | 09 Mar 2025 | Option execute | 2,667 | - | - |
| Date | Type | Details |
|---|---|---|
| 12 Mar 2025 | Announcement | Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories |
| 04 Mar 2025 | Announcement | Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results |
| 18 Feb 2025 | Announcement | Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 |
| 21 Jan 2025 | Announcement | Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies |
| 14 Jan 2025 | Announcement | Moffitt Cancer Center and Cryoport Announce Strategic Collaboration |
| 06 Jan 2025 | Announcement | Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA") |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |